Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis

INTRODUCTION: BAY 94-9027 is a newly developed extended half-life product to treat haemophilia, allowing for fewer injections than with standard products. This post hoc analysis aimed to compare physicians’ and patients’ opinions on BAY 94-9027 prophylaxis, and explore how qualitative interview data...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalezari, Shadan, Acquadro, Michaël, de Bock, Elodie, Lambert, Jérémy, Simpson, Mindy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467448/
https://www.ncbi.nlm.nih.gov/pubmed/32410165
http://dx.doi.org/10.1007/s12325-020-01374-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467448/
https://www.ncbi.nlm.nih.gov/pubmed/32410165
http://dx.doi.org/10.1007/s12325-020-01374-2

Ejemplares similares